Bausch Health Cos
Bausch Health Companies Inc is a Canadian global pharmaceutical company developing and manufacturing prescription and over-the-counter healthcare products. The company manufactures gastrointestinal therapeutics, dermatological treatments, neurological medicines, and eye health products through its Bausch + Lomb subsidiary. Main revenue drivers comprise global sales of branded prescription pharmaceuticals like Xifaxan alongside vision care supplies, contact lenses, and surgical equipment. Bausch Health serves gastroenterologists, dermatologists, ophthalmologists, hospital networks, and retail patients across North America, Europe, and Asia. The company maintains an established market position in specialty gastroenterology and global eye health care. Headquartered in Laval, Quebec, Canada, Bausch Health Companies Inc is listed on the Toronto Stock Exchange and New York Stock Exchange.
15 of the funds FundTelligence covers report a position in Bausch Health Cos.
- Legal name
- BAUSCH HEALTH COS INC
- Sector
- Health Care
- Country
- Canada
- Funds holding it
- 15
Funds holding Bausch Health Cos
- Nordea US High Yield Bond — Nordea Funds · 0.49 % (full portfolio disclosed, September 2026)
- Nordea US High Yield Sustainable Stars Bond Fund — Nordea Funds · 0.35 % (full portfolio disclosed, September 2026)
- Nordea Global High Yield Bond Fund — Nordea Funds · 0.3 % (full portfolio disclosed, September 2026)
- Nordea Global High Yield Enhanced Bond Fund — Nordea Funds · 0.3 % (full portfolio disclosed, September 2026)
- Nordea Global High Yield Sustainable Stars Bond Fund — Nordea Funds · 0.22 % (full portfolio disclosed, September 2026)
- Mercer Global High Yield Bond Fund — Mercer · 0.19 % (full portfolio disclosed, December 2025)
- Nordea Virksomhedsobligationer Højrente — Nordea Funds · 0.14 % (full portfolio disclosed, September 2026)
- Danske Invest Global High Yield Obligasjon — Danske Invest · 0.14 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 15 funds holding it.